In the following video, Motley Fool health-care analyst David Williamson highlights one pharmaceutical company that has no interest in organic growth. Valeant Pharmaceuticals (VRX 2.98%) is continuing its growth-through-acquisition strategy with the purchase of Obagi Medical Products (NASDAQ: OMPI), its 21st acquisition since 2011, for $344 million. David tells investors why this is a win for both parties, and how they should think of the investing thesis behind Valeant.
Valeant Continues to Devour
By Dave Williamson – Mar 20, 2013 at 7:26PM
NYSE: BHC
Bausch Health Companies
Market Cap
$2.3B
Today's Change
(-2.98%) $0.19
Current Price
$6.19
Price as of October 24, 2025 at 3:58 PM ET
The pharma continues to gobble up smaller business snacks.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid